KC-2651

CHOK1-mouse-LY6G6D Cell Line

×
24486
Home » CHOK1-mouse-LY6G6D Cell Line

Background of CHOK1-mouse-LY6G6D Cell Line

LY6G6D encodes lymphocyte antigen 6 family member G6D and is also known as G6D. LY6G6D belongs to a cluster of leukocyte antigen-6 (LY6) genes located in the major histocompatibility complex (MHC) class III region on chromosome 6. Members of the LY6 superfamily typically contain 70 to 80 amino acids, including 8 to 10 cysteines. Most LY6 proteins are attached to the cell surface by a glycosylphosphatidylinositol (GPI) anchor that is directly involved in signal transduction (Mallya et al., 2002 [PubMed 12079290]).[supplied by OMIM, Apr 2009]

Specifications

Catalog NumberKC-2651
Cell Line NameCHOK1-mouse-LY6G6D Cell Line
Clone Number1#
Host Cell LineCHOK1
DescriptionCHOK1-mouse-LY6G6D is a stable engineered cell line expressing mouse LY6G6D
QuantityOne vial of frozen cells (≥2×10⁶ cells/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640+20% FBS+10% DMSO
Propagation MediumRPMI1640+10%FBS+10μg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit at a ratio of 1:4–1:6 every 2–3 days
Incubation37 °C with 5% CO₂
StorageLiquid nitrogen immediately upon receiving
Doubling TimeEstimated 19–36 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

CHOK1-mouse-LY6G6D cell line was generated using a lentiviral vector expressing the mouse LY6G6D sequence.

Characterization

Figure: Characterization of mouse LY6G6D overexpression in CHOK1 stable clones using Quantitative real-time PCR.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO₂ incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4–1:6 every 2–3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

  1. Naqvi M, Abbasi WA, Samma MK et al. Decoding LY6G6D in colorectal cancer: Unraveling biomarker potential and therapeutic insights. Cellular and molecular biology (Noisy-le-Grand, France). 2024 Jun 5;70(6):14-20. PMID: 38836687. doi: 10.14715/cmb/2024.70.6.3.
  2. Sanvicente García A, Pedregal M, Paniagua-Herranz L et al. Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D. International journal of molecular sciences. 2024 May 14;25(10):. PMID: 38791382. doi: 10.3390/ijms25105345.
  3. Corrales L, Hipp S, Martin K et al. LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager. Frontiers in immunology. 2022;13:1008764. PMID: 36159851. doi: 10.3389/fimmu.2022.1008764.

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.